Table 1.
Target-specific oral anticoagulant | Target | Time to peak concentration (h) | Half-life (h) | Renal excretion |
---|---|---|---|---|
Dabigatran [28,29] | Thrombin | 1–3 | 7–9a 7–17b |
80–85% |
Rivaroxaban[30–32] | Factor Xa | 2–4 | 7–17a 12–13c 6–9b |
36% |
Apixaban [33–35] | Factor Xa | 1–3 | 8–14a | 25% |
Edoxaban [36] | Factor Xa | 1–2 | 6–11a 9–10b |
36–45% |
Betrixaban [36,37] | Factor Xa | 3–4 | 19 | <8% |
Healthy adults, single dose.
Healthy adults, multiple doses.
Healthy elderly, single dose.